Tissue distribution and biotransformation of zopolrestat, an aldose reductase inhibitor, in rats.
Zopolrestat (Alond) is a new drug that is being evaluated as an aldose reductase inhibitor for the treatment of diabetic complications. 14C-labeled zopolrestat was orally administered to rats for a tissue distribution study and a bile duct cannulation metabolism study. Tissue samples from the distribution study were analyzed by complete oxidation and liquid scintillation counting. Urine and bile samples from the bile duct cannulation study were analyzed by microbore HPLC, with simultaneous radioactivity monitoring and atmospheric pressure ionization tandem mass spectrometry. The mass balance in the distribution study demonstrated that the greatest exposure (AUC0-infinity) occurred in the liver, followed by the ileum and large intestine. The time of maximal plasma concentrations for nearly all tissues was 4 hr after the dose, and the half-life of radioactivity in most tissues (8-10 hr) was similar to the half-life in plasma. For the bile duct-cannulated rat study, most of the radioactivity was recovered in the bile, indicating that biliary excretion is a major route of elimination of zopolrestat and its metabolites in rats. Numerous oxidative metabolites, as well as phase II conjugates, were identified in the bile and urine samples. Acyl glucuronides of zopolrestat and unchanged drug accounted for >85% of biliary radioactivity, whereas unchanged drug and degradation products of glutathione conjugates were identified as the major urinary metabolites.
Schneider
R P
RP
Drug Metabolism Department, Central Research Division, Pfizer Inc., Groton, CT 06340, USA.
Fouda
H G
HG
Inskeep
P B
PB
D000284:Administration, Oral; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D052160:Benzothiazoles; D001652:Bile Ducts / Q000378:metabolism; D001711:Biotransformation; D002851:Chromatography, High Pressure Liquid; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006207:Half-Life; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D013058:Mass Spectrometry; D010793:Phthalazines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051381:Rats; D020318:Rats, Long-Evans; D013844:Thiazoles / Q000008:administration & dosage / Q000493:pharmacokinetics*; D014018:Tissue Distribution
D052160:Benzothiazoles; D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D010793:Phthalazines; D013844:Thiazoles; C067172:zopolrestat; D000449:Aldehyde Reductase